Acadia Pharmaceuticals (ACAD) Equity Ratio (2010 - 2026)

Acadia Pharmaceuticals' Equity Ratio history runs 17 years deep, the most recent figure standing at 0.78 for Q1 2026.

• In Q1 2026, Equity Ratio rose 15.05% year-over-year to 0.78; the TTM figure through Mar 2026 stood at 0.78 (up 15.05% YoY), while the FY2025 annual figure was 0.78, up 27.19% from the prior year.
• Equity Ratio was 0.78 for Q1 2026 at Acadia Pharmaceuticals, down from 0.78 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.78 in Q4 2025 to a low of 0.54 in Q1 2024.
• Historically, Equity Ratio has averaged 0.65 across 5 years, with a median of 0.67 in 2025.
• The sharpest annual moves came in 2023 and 2025: Equity Ratio dropped 19.85% in 2023, then rose 27.19% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.68 in 2022, then declined by 15.37% to 0.58 in 2023, then gained by 7.02% to 0.62 in 2024, then grew by 27.19% to 0.78 in 2025, then declined by 0.91% to 0.78 in 2026.
• The last three Equity Ratio figures came in at 0.78 (Q1 2026), 0.78 (Q4 2025), and 0.69 (Q3 2025), per Business Quant data.